In general, long-term outcomes of lipid perturbations on metabolic diseases as well as on related morbidity and mortality in patients with HNF4A-MODY, GCK-MODY, HNF1A-MODY, and HNF1B-MODY require future investigations. This evidence concerns the gene HNF1A and Other metabolic disease.